Skip to main content
. 2023 Mar 31;16(4):526. doi: 10.3390/ph16040526

Table 2.

Previous treatments of enrolled patients.

Previous Treatments n (%)
77 (100)
Topical treatments 10 (12.9)
Methotrexate 14 (18.2)
Cyclosporine 21 (27.3)
Acitretin 3 (3.9)
NB-UVB 4 (5.2)
Dimethyl fumarate 3 (3.9)
Apremilast 8 (10.4)
Adalimumab 2 (2.6)
Ustekinumab 2 (2.6)
Secukinumab 7 (9.1)
Others (etanercept, brodalumab) 3 (3.9)